{
  "schemaVersion": 1,
  "id": "research-159",
  "slug": "159-why-the-heart-outcomes-trial-used-an-active-comparator",
  "title": "Why the heart outcomes trial used an active comparator",
  "catalogLabel": "GLP-2 TIRZ",
  "productCollection": "https://heritagebiolabs.com/research-library/products/glp-2-tirz",
  "productHandles": [
    "glp-2-tirz-691",
    "glp-2-tirz-714"
  ],
  "productUrls": [
    "https://heritagebiolabs.com/product/glp-2-tirz-691",
    "https://heritagebiolabs.com/product/glp-2-tirz-714"
  ],
  "readingFocus": "Interpreting evidence",
  "readingFocusNote": "Reading focus is a navigational tag, not an evidence grade.",
  "wordCount": 346,
  "sourceYears": [
    2022,
    2025,
    2026
  ],
  "paragraphs": [
    "Peptides are short chains of amino acids joined by peptide bonds. Some are designed to engage more than one receptor. Tirzepatide activates GIP and GLP-1 receptors. The catalog wording “GLP-2 TIRZ” refers to tirzepatide and does not identify a GLP-2 target. The SURPASS-CVOT trial compared tirzepatide with dulaglutide to assess major cardiovascular events in adults with type 2 diabetes and atherosclerotic cardiovascular disease. [1, 2]",
    "Dulaglutide is a GLP-1 receptor agonist with previous evidence on cardiovascular events. Comparing two active treatments addressed what happened when participants were assigned to tirzepatide or a drug already used in that setting. The researchers tracked a combined outcome of cardiovascular death, heart attack or stroke. More than 13,000 people underwent randomization. About 12.2% in the tirzepatide analysis group and 13.1% in the dulaglutide group experienced a primary outcome event. [1]",
    "The trial was designed to test noninferiority. Before starting, the investigators set a statistical margin for how much worse tirzepatide could be and still meet their specified standard. The hazard ratio was 0.92, with a confidence interval from 0.83 to 1.01 under the trial’s calculation. The upper bound met the noninferiority margin. It crossed 1.00, and the trial did not establish statistical superiority on the primary outcome. The distinction helps explain why a lower event percentage alone does not settle whether one treatment outperformed the other. [1]",
    "The 2026 U.S. Mounjaro label includes reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for those events. That is a labeled indication for the particular product. The trial result describes a comparison with dulaglutide among adults who already had atherosclerotic cardiovascular disease. It does not estimate what would have happened with placebo in the same randomized population. [1, 3]",
    "The study also recorded adverse events and reported more gastrointestinal events in the tirzepatide group. This is part of the head-to-head evidence, alongside the event counts and the uncertainty around the estimate. Reading the comparator, population and prespecified statistical question together provides a more accurate account than simply comparing the two percentages. [1]"
  ],
  "sources": [
    {
      "number": 1,
      "citation": "Stephen J. Nicholls et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. The New England Journal of Medicine (publication 2025-12-01).",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41406444/"
    },
    {
      "number": 2,
      "citation": "Bingfa Sun et al. Structural determinants of dual incretin receptor agonism by tirzepatide. Proceedings of the National Academy of Sciences (publication 2022-03-25).",
      "url": "https://pubmed.ncbi.nlm.nih.gov/35333651/"
    },
    {
      "number": 3,
      "citation": "U.S. Food and Drug Administration. MOUNJARO (tirzepatide) injection, prescribing information. Drugs@FDA (publication 2026-08).",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s044s045lbl.pdf"
    }
  ],
  "canonicalUrl": "https://heritagebiolabs.com/research-library/articles/159-why-the-heart-outcomes-trial-used-an-active-comparator",
  "markdownUrl": "https://heritagebiolabs.com/research-library/data/articles/159-why-the-heart-outcomes-trial-used-an-active-comparator.md",
  "jsonUrl": "https://heritagebiolabs.com/research-library/data/articles/159-why-the-heart-outcomes-trial-used-an-active-comparator.json",
  "provenance": {
    "sourceArchive": "Peptide Research Articles - All 82 Volumes.zip",
    "sourceArchiveSha256": "9796bec477cbe2f8017dda81c7e58260985a13bdda1f934e8eb8d0549c2cada5",
    "sourceVolume": "Peptide Research Articles 032 - GLP-1 SEMA and GLP-2 TIRZ.docx",
    "sourceArticleNumber": 159,
    "contentSha256": "1ccc5d0d76a814e45cb0551f0db3f385bb63751b588f78dcafa5fa070f7195f8",
    "statement": "Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed."
  },
  "scope": "Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend."
}
